Quebec-City-based Medicago, a subsidiary to Japan-based Mitsubishi Tanabe Pharma, reports a breakthrough in the fight against the coronavirus outbreak, making a claim that it has developed a COVID-19 vaccine candidate that could begin human testing as early as this summer. The venture reports it has produced a virus-like particle of the novel coronavirus, a first step toward producing a vaccine, which will now commence pre-clinical testing for safety and efficacy.
Who is Medicago?
Founded back in 1997, Medicago formed a partnership between Agriculture and Agri-Food Canada and the University of Laval, the company’s majority shares were acquired by Japanese company Mitsubishi Tanabe Pharma in 2013. They are a biotech company focusing on the research, development, production, and commercialization of vaccines in Canada. They develop vaccines based on their proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. They have a number of collaborative agreements in place, including with Viridis S.A. and Philip Morris International.
Medicago Vaccine Success Track Record
Medicago is a leader in plant-based technology, ha...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).